MGN1331 - DNA vaccine against leishmaniasis

About leishmaniasis

Around 12 million people around the world, with growing geographical distribution, in 88 countries on four continents, are currently infected with leishmaniasis and the trend is increasing considerably. This debilitating and often fatal infectious disease affecting humans and animals is therefore currently one of the 14 "neglected diseases" which the World Health Organization is stepping up its efforts to fight.

According to estimates by the WHO, more than a billion people worldwide suffer from these "neglected diseases".  MOLOGEN AG is engaging in the battle against leishmaniasis.  Together with highly respected research institutions from all over the world, the company is currently developing its innovative MGN1331 vaccine to help prevent and treat this disease.

Internal leishmaniasis causes particularly severe effects in individuals concurrently infected with HIV due to the weakened immune system. The global demand for medically effective prevention and treatment is enormous:  Experts estimate that around 500,000 people per year develop the severe form of leishmaniasis, which claims over 50,000 lives annually. 

MGN1331 - joint research in a consortium

MOLOGEN AG recognized the potential of innovative DNA vaccines against leishmaniasis early on.  Its own MIDGE® platform technology forms the basis for prophylactic and therapeutic DNA vaccines. The vaccine showed highly promising results for prophylactic and therapeutic application in animal models along with very ggod tolerability. Preclinical development has been completed successfully.

In the complex process of developing a vaccine against leishmaniasis, MOLOGEN AG has teamed up with international partners from the field of leishmaniasis research.  The consortium received extensive financial support from funds provided by the European Union.

The aim of the leishdnavax research project was to develop a prophylactic and therapeutic DNA vaccine against leishmaniasis.  

Due to limited financial resources and the focus on lefitolimod, it is not possible to substantially progress this project. Consequently, MOLOGEN intends to sell off the MIDGE® technology together with all the associated compounds; a spin-off is conceivable as an alternative.